血清HE4浓度区分恶性卵巢肿瘤和卵巢子宫内膜异位囊肿

目的：人类附睾分泌蛋白HE4,也称为WAP四二硫化物核心域蛋2,是卵巢癌新有希望的生物标志物,但其对卵巢子宫内膜异位囊肿特异性只是少许了解而已。方法：分析诊断为不同类型的子宫内膜异位症,子宫内膜癌或卵巢癌,健康对照样品的血清HE4浓度连同血清CA125。结果：HE4的平均血清浓度为显著高在子宫内膜癌（98.3pM,P〈0.01）和卵巢癌（1135.1pM,P〈0.01）患者,但在卵巢子宫内膜异位（47.0pM）或其他类型的子宫内膜异位症（46.2pM）不高,与健康对照组（39.5pM）相比。血清CA125浓度升高与卵巢癌患者,子宫内膜异位症累积腹膜或深部病变的患者,或卵巢子宫内膜异位囊肿,但不是在子宫内膜癌患者升高。微阵列结果显示,编码HE4和CA125基因的mRNA的表达反映了血清蛋白浓度。结论：同时测量HE4和CA125血清浓度会增加卵巢癌诊断的准确性,并提供有价值的信息鉴别卵巢子宫内膜异位囊肿和卵巢肿瘤。

Serum HE4 Levels differentiating Malignant Ovarian Mass from ovarian endometriomas

Objective： Human epididymal secretory protein E4, also called WAP four--disulphide core do- main protein 2, is a new potential biomarker for detection of ovarian cancer, while its specificity toward ovarian endometriotic cysts until now is not clear. Methods： Our research analyzed serum HE4 levels and CA125 in serum samples of women who were diagnosed with various subtypes of ovarian cancer or endometrial cancer in healthy controls. Results： Compared with healthy controls （39.5pM）, the HE4 mean serum levels was signifi- cantly high among patients with both ovarian cancer （1135. 1pM, P 〈 0. 01） and endometrial （98. 3pM, P 〈 0. 01）, but the level in ovarian endometriomas （47.0pM） or other subtypes of endometriosls （46. 2pM） ws not high. The serums CA 125 were elevated among patients with advanced endometriosis, ovarian cancer, o- varian endometriomas, or with peritoneal or deep lesions, but not among those with endometrial cancer. The microarray results showed that the mRNA expression of the genes encoding HE4 and CA125 reflected the serum protein concentrations. Conclusion： Taken together, measuring both HE4 and CA125 serum concentra- tions could increases the accuracy of ovarian cancer diagnosis and provide valuable information to discriminate o- varian tumours from ovarian endometriotic cysts.